Committed to sharing our science

Committed to sharing our science

335 results available

The Effect of Omecamtiv Mecarbil on Stroke in Patients With Heart Failure and Reduced Ejection Fraction in GALACTIC-HF

Presentation, American Heart Association (AHA) Scientific Sessions 2021
Teerlink, JR, et al
Virtual
November 13, 2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure

JAMA Cardiology
Felker GM, Solomon SD, Claggett B, et al
October 13, 2021
Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function

Journal of Medicinal Chemistry
Collibee SE, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, Jamison CR, Lu K, Lu P, et al.
October 12, 2021
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Journal of Medicinal Chemistry
Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzy J, Wehri E, Robertson LA, Malik FI, Morgan BP
October 4, 2021
REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy

Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Maron, M, et al
Denver, CO
September 12, 2021